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ABSTRACT
The molecular chaperone Heat shock protein 90 (Hsp90) is essential for the
folding, stability, and activity of several drivers of oncogenesis. Hsp90 inhibitors are
currently under clinical evaluation for cancer treatment, however their efficacy is
limited by lack of biomarkers to optimize patient selection. We have recently identified
the tumor suppressor tuberous sclerosis complex 1 (Tsc1) as a new co-chaperone
of Hsp90 that affects Hsp90 binding to its inhibitors. Highly variable mutations of
TSC1 have been previously identified in bladder cancer and correlate with sensitivity
to the Hsp90 inhibitors. Here we showed loss of TSC1 leads to hypoacetylation
of Hsp90-K407/K419 and subsequent decreased binding to the Hsp90 inhibitor
ganetespib. Pharmacologic inhibition of histone deacetylases (HDACs) restores
acetylation of Hsp90 and sensitizes Tsc1-mutant bladder cancer cells to ganetespib,
resulting in apoptosis. Our findings suggest that TSC1 status may predict response to
Hsp90 inhibitors in patients with bladder cancer, and co-targeting HDACs can sensitize
tumors with Tsc1 mutations to Hsp90 inhibitors.

INTRODUCTION

the invasive monitoring required in the management of
this disease [3]. Depending on stage, standard of care
in management of bladder cancer may include local
resection, chemotherapy, immunotherapy, radiotherapy,
or partial or radical cystectomy [4]. Advancements in
the treatment of metastatic disease have been few, with
alternatives to chemotherapeutic mainstay therapies
offering limited survival benefit [5, 6].
The molecular chaperone heat shock protein-90
(Hsp90) is essential for the stabilization and activation
of many oncogenic proteins, known as clients, involved

Over 80,000 people will be diagnosed with bladder
cancer and approximately 18,000 patients will die
from this disease in the United States in 2019 [1]. The
vast majority of bladder cancer cases are urothelial cell
carcinomas (90%) followed by squamous cell carcinomas
(5%) with the remaining cases being made up of rare
entities including sarcoma and small cell carcinoma
[2]. Bladder cancer has the highest lifetime cost of all
cancers, which is attributed to high recurrence rates and
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express wild-type (WT) TSC1 as well as RT4 cells that
have a TSC1 mutation (1669delC), which leads to a
frame shift and premature stop codon, rendering the
protein product (Tsc1-L557Cfs) unstable (Figure 1A, 1B;
Supplementary Figure 1A) [27]. Our data showed that
Hsp90 binding was significantly reduced in TSC1 mutated
RT4 cells compared to TSC1 WT T24 and UM-UC-3
bladder cancer cells (Figure 1B, Supplementary Figure
1B). We have further demonstrated that presence of Tsc1
facilitates accumulation of fluorescently-tagged Hsp90
inhibitor, BODIPY-ganetespib, in bladder cancer cells
after 4 hours of treatment (Figure 1C, 1D; Supplementary
Figure 1C–1E). This ganetespib accumulation was
reduced when TSC1 was silenced by siRNA in T24 and
UM-UC-3 cells (Figure 1C, 1D; Supplementary Figure
1C, 1D). Conversely, re-expression of WT Tsc1 in RT4
cells restored uptake and retention of ganetespib in these
bladder cancer cells (Figure 1C, 1D; Supplementary
Figure 1C, 1E). In addition to the effect on inhibitor
accumulation, TSC1 expression also significantly
sensitized RT4 bladder cancer cells to Hsp90 inhibitor
as evidenced by WST proliferation assay (Figure 1E).
Conversely, silencing of TSC1 in T24 and UM-UC-3 cells
reversed their sensitivity to ganetespib. Taken together,
these data show that presence of Tsc1 enhances bladder
cancer cell sensitivity and uptake of Hsp90 inhibitors.

in malignant transformation of tumor cells [7–9]. Hsp90
chaperone function is coupled to its ability to bind and
hydrolyze ATP [10–12]. This ATPase activity provides
directionality to the Hsp90 chaperone cycle, which is
tightly regulated by both co-chaperone proteins and posttranslational modifications [13–15]. Numerous small
molecules have been identified that compete with ATP
for binding to the amino-domain of Hsp90 and inhibit its
chaperone function, leading to the degradation of many
client proteins involved in tumorigenesis [7]. There are
currently 7 Hsp90 inhibitors in clinical trials (https://www.
clinicaltrials.gov/), and there is an urgent need to identify
biomarkers to help identify those patients that would
respond favorably to treatment with Hsp90 inhibitors [16].
We have recently identified the tumor suppressor
TSC1 as a novel regulator/co-chaperone of Hsp90
important for the folding and stability of numerous kinase
and non-kinase clients including Tsc2 protein (tuberin)
[17]. Tsc2 protein has a GTPase-activating function and in
complex with Tsc1 protein (hamartin) and possibly Hsp90
acts as a negative regulator of AMPK/mTOR signaling
[18–20]. Additionally, Tsc1 assists in the deceleration of
Hsp90 ATPase activity and the Hsp90 chaperone cycle,
and Tsc1 expression increases Hsp90 binding to its
inhibitors [17].
Mutation and inactivation of the tumor suppressor
TSC1 has been found in approximately 15% of bladder
cancers and loss of heterozygosity of a region spanning
the TSC1 locus at 9q34 has been seen in roughly 54% of
bladder cancers [21–26]. We therefore hypothesized that
mutation and inactivation of TSC1 in bladder cancer cells
leads to decreased sensitivity to Hsp90 inhibitors. Our
data supported this hypothesis, and we mechanistically
demonstrated that mutation and loss of TSC1 in bladder
cancer cells causes hypoacetylation of Hsp90-K407/
K419 and subsequent decreased binding of Hsp90 to its
inhibitor ganetespib. Pharmacologic inhibition of histone
deacetylases (HDACs) restores acetylation of Hsp90 and
sensitizes Tsc1-mutant bladder cancer cells to ganetespib,
resulting in apoptosis. Our results suggest that Tsc1 status
can predict response to Hsp90 inhibition in bladder cancer
patients and further provide a strategy to co-target HDACs
and Hsp90 in bladder cancers with mutation in TSC1.

Tsc1 facilitates acetylation of Hsp90
Previous studies from our lab and others have shown
that post-translation modification (PTM) of Hsp90 impacts
its binding to as well as sensitizes cells to Hsp90 inhibitors
[15, 28–30]. We therefore asked whether absence of Tsc1
impacts the PTM of Hsp90. We showed hypoacetylation
of Hsp90 in CRISPR/Cas9 TSC1 KO HAP1 compared to
WT HAP1 cells (Figure 2A; Supplementary Figure 2A).
Interestingly, lack of TSC1 did not affect phosphorylation
of Hsp90 on serine, threonine, or tyrosine residues (Figure
2A). Expression of WT TSC1 in TSC1 KO HAP1 cells
restored acetylation of Hsp90, however we did not obtain
similar results upon overexpression of Tsc1-L557Cfs
(Figure 2B). We made a similar observation in RT4 cells,
which contain the Tsc1-L557Cfs mutation and showed
hypoacetylation of Hsp90 relative to WT Tsc1 containing
T24 and UM-UC-3 cells (Figure 2C). It is noteworthy
that overexpression and stabilization of this mutant
does not restore its binding to Hsp90, likely because it
lacks the C-terminal region of Tsc1 that binds to Hsp90
(Supplementary Figure 2B) [17].
Our previous work has shown that the conditional
knockout of TSC1 in mouse brain (Tsc1GFAPCKO) caused
a significant increase in ATPase activity compared to the
control samples [17]. Using those samples, we showed
that Hsp90 is also hypoacetylated in Tsc1GFAPCKO tissue
(Figure 2D, LE=long exposure, SE=short exposure).
Therefore, we asked whether a similar phenomenon was

RESULTS
Tsc1 expression determines Hsp90 inhibitor
accumulation and sensitivity in bladder cancer
cells
Our previous study has shown that the presence of
Tsc1 co-chaperone, which interacts with Hsp90 through
the C-terminus of Tsc1, enhances Hsp90 binding to
its inhibitors in cells [17]. Here, we used biotinylated
inhibitor ganetespib (GB-biotin) to determine the binding
affinity of Hsp90 from T24 and UM-UC-3 cells, which
www.oncotarget.com
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Figure 1: Tsc1 expression determines Hsp90 inhibitor accumulation and sensitivity in bladder cancer cells. (A) Tsc1

status in T24, UM-UC-3 and RT4 bladder cancer cell lines was assessed by immunoblot. GAPDH was used as a loading control. (B) Lysates
from Figure 1A were challenged with biotinylated-ganetespib. Binding of Hsp90 from T24, UM-UC-3 and RT4 cells to biotinylatedganetespib was examined by immunoblot. (C) TSC1 was targeted by siRNA in T24 and UM-UC-3 cells and Tsc1-FLAG was transiently
expressed in RT4 cells. Representative confocal microscopy images of these cells treated for 4hr with BODIPY-ganetespib at the indicated
concentrations and stained with DAPI. Scale bar = 50 µm. (D) Quantification of average fluorescence intensity of BODIPY-ganetespib in
(C). A Student’s t-test was performed to assess statistical significance (**p < 0.01). (E) TSC1 was targeted by siRNA in T24 (left) and UMUC-3 (center) and Tsc1-FLAG was transiently expressed in RT4 (right) cells for 48 hr. Following this, cells were treated for an additional
72 hr with the indicated concentrations of ganetespib. Cell proliferation was assessed by WST proliferation assay. A Student’s t-test was
performed to assess statistical significance (*p < 0.05; **p < 0.01).
www.oncotarget.com
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Figure 2: Tsc1 facilitates acetylation of Hsp90. (A) Hsp90 was immunoprecipitated from TSC1 KO and TSC1 WT HAP1 cells and

its serine, threonine, and tyrosine phosphorylation and lysine acetylation were examined by immunoblot. IgG was used as a control. (B)
TSC1 KO HAP1 cells were transiently transfected with EV, Tsc1-TW-FLAG or Tsc1-L557Cfs-FLAG (mut.), the mutation found in the
RT4 cell line. Acetylation of Hsp90 was then determined by immunoprecipitation and immunoblot. (C) Acetylation status of Hsp90 in T24,
UM-UC-3 and RT4 determined by immunoprecipitation and immunoblot. (D) Hsp90 was immunoprecipitated from WT and astrocytespecific TSC1 KO mouse brain lysate and serine, threonine, and tyrosine phosphorylation and lysine acetylation of Hsp90 were assessed by
immunoblot. LE=long exposure, SE=short exposure. (E) ATPase activity of Hsp90 isolated from TSC1 WT and TSC1 KO HAP1 cells. 10
µM ganetespib was used as a control. A Student’s t-test was performed to assess statistical significance (n. s., not significant; *p < 0.05; ***p
< 0.001). (F) Endogenous Hsp90 was isolated from MEF WT, Tsc1 KO or Tsc2 KO cells and acetylation was examined by immunoblot.
Tsc1 and Tsc2 status was also examined. (G) HEK293 cells transiently expressing Hsp90α-WT-FLAG and empty plasmid (EV) was treated
with rapamycin (20 nM) for 1 hr. Hsp90α-WT-FLAG was immunoprecepitated and its acetylation was evaluated by immunoblot. p70S6K
and p-p70S6K (T389) were used to examine the inhibition of mTOR pathway.
www.oncotarget.com
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present in the TSC1 KO HAP1 cells. In agreement with
our previously published data [17], we found that Hsp90
isolated from TSC1 KO cells displayed increased ATPase
activity compared to Hsp90 from WT HAP1 cells (Figure
2E; Supplementary Figure 2C, 2D).
Finally, Tsc1-Tsc2 are involved in negatively
regulating the mTOR signaling pathways. We therefore
asked whether the effect of the Tsc1 mutation on Hsp90
acetylation is independent of mTOR pathway. Endogenous
Hsp90 isolated from TSC2 knock out mouse embryonic
fibroblast cells (MEF) had a similar level acetylation as
the Hsp90 isolated WT MEF cells (Figure 2F). As expected
Hsp90 from TSC1 KO MEF cells was hypoacetylated
(Figure 2F). Additionally treating HEK293 cells with
rapamycin did not impact acetylation of Hsp90 (Figure 2G)
suggesting the effect of Tsc1 mutation or loss on Hsp90
acetylation is not mediated through the mTOR pathway.
Taken together, our results show that mutation
and loss of Tsc1 stability and expression leads to
hypoacetylation of Hsp90 and enhanced Hsp90 ATPase
activity.

results demonstrate that lack of Tsc1 expression leads to
hypoacetylation of Hsp90 on K407/K419 and subsequent
reduced binding of Hsp90 to its inhibitors.

Tsc1 facilitates acetylation of Hsp90-K407/K419

HDAC inhibition synergizes with Hsp90
inhibition to induce apoptosis in bladder cancer

HDAC inhibition rescues Hsp90 acetylation in
TSC1-knock out cells
Histone deacetylases (HDAC) modify Hsp90
[14, 31, 32], therefore we treated HEK293 cells with an
HDAC inhibitor ACY-241 (acts as a pan-HDAC inhibitor
at high dosage) for 16 hours, and showed hyperacetylation
of Hsp90 (Figure 4A; Supplementary Figure 4A). We
further utilized this pan-HDAC inhibitor to demonstrate
that treatment of HEK293 cells expressing Hsp90αK407A/K419A does not increase the acetylation on
this mutant (Figure 4B). This suggests that the effect of
HDAC inhibition on Hsp90 is likely only through K407
and K419. Finally, endogenous Hsp90 from TSC1 KO
HAP1 cells is hypoacetylated but treating these cells with
the HDAC inhibitor ACY-241 rescued Hsp90 acetylation
(Figure 4C, Supplementary Figure 4B).

Hypoacetylation of Hsp90 leads to its elevated
ATPase activity; we therefore reasoned that lysine residues
within the catalytic region of Hsp90 are candidates for
PTMs. We identified two lysine sites (K407/K419)
within this region that have been reported to be subject
to acetylation (https://www.phosphosite.org//homeAction.
action; Figure 3A). We mutated these lysine residues to
non-acetylatable alanine in Hsp90α individually and in
combination and exogenously expressed them in CRISPR/
Cas9 HSP90AA1 KO HAP1 cells (Supplementary
Figure 3A). Our data showed a reduction in acetylation
of Hsp90α-FLAG-K407A and K419A and significant
hypoacetylation of Hsp90α-FLAG-K407A/K419A
suggesting that both of these residues are subject to
acetylation (Figure 3B). It is noteworthy that K407 and
K419 are not the only lysine sites that are acetylated on
Hsp90α. Longer-exposure of immunoblots in Figure 3B
confirms acetylation of Hsp90α and its mutants. Using
anti-FLAG M2 agarose, we immunoprecipitated WT
Hsp90α-FLAG as well as the lysine to alanine mutants
from these cells and showed that Tsc1 interaction was
completely abrogated in the K407A/K419A (AA) mutant
(Figure 3C). We further demonstrated that Hsp90 was
hypoacetylated in CRISPR/Cas9 TSC1 KO HAP1 cells
to the same levels as the K407A/K419A (AA) mutant
(Figure 3D), suggesting these lysine residues were
the only sites affected as the result of TSC1 deletion.
Finally, we demonstrated a significant reduction in
binding of Hsp90α-K407A/K419A to biotinylated
ganetespib, which demonstrates that acetylation of these
two residues are important for Hsp90 inhibitor binding
(Figure 3E, Supplementary Figure 3B). In aggregate, our
www.oncotarget.com

Mutation and inactivation of TSC1 in bladder cancer
cells leads to decreased sensitivity to Hsp90 inhibitors. It
appears that loss of Tsc1 may mediate this effect through
Hsp90 hypoacetylation, which subsequently decreases
Hsp90 inhibitor binding. We therefore treated the bladder
cancer cells with a pan-HDAC inhibitor with the goal
of restoring Hsp90 acetylation in Tsc1-mutant cells and
subsequent sensitivity to Hsp90 inhibitors. Our initial data
showed that Tsc1 mutated RT4 cells are more sensitive
to the pan-HDAC inhibitor ACY-241 than WT Tsc1
T24 or UM-UC-3 cells (Figure 5A), presumably due
to hyperactivity of HDACs. We next treated RT4 cells
with 50nM ACY-241 for 16 hours, followed by 500 nM
ganetespib for further 48 hours. We further show that
the co-treatment of ACY-241 and ganetespib yields a
combination index score <1, (0.79412; Supplementary
Figure 5A). Our results demonstrated synergistic effect of
combination HDAC and Hsp90 inhibitor treatment on RT4
cell proliferation (Figure 5B). Of note, the inhibitor doses
used in the combination treatment were significantly lower
than the IC50s of these drugs for RT4 cells. Additionally,
combination treatment led to increased apoptosis as
observed by immunoblot of cleaved caspase-3 (Figure 5C,
Supplementary Figure 5B). We further confirmed that the
sensitization of RT4 cells towards Hsp90 inhibitors as a
result of HDAC co-inhibition was due to enhanced affinity
of Hsp90 for ganetespib using biotinylated ganetespib
binding assay (Figure 5D). Overall, our data provide
evidence that inhibition of HDACs in bladder cancer cells
that lack Tsc1 provides a strategy to enhance the efficacy
of Hsp90 inhibitors.
5828
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DISCUSSION

reintroducing WT Tsc1 suggesting that it is a Tsc1-specific
effect.
Previous work by our group and others has
shown that PTM of Hsp90 can modulate its binding
and sensitivity to Hsp90 inhibitors [28–30, 33–35], we
therefore asked whether Hsp90 was differentially modified
in the absence of Tsc1. Mechanistically, we demonstrated
that presence of Tsc1 resulted in acetylation of two lysine
residues (K407/K419) near the catalytic site in the middledomain of Hsp90. Mutation or absence of TSC1 led to
hypoacetylation of Hsp90 and this was demonstrated
in Hsp90 isolated from four cell types lacking TSC1: 1)

The tumor suppressor TSC1 is a new co-chaperone
of Hsp90 that modulates Hsp90 activity and enhances
Hsp90 binding to its inhibitors [17, 20]. Mutations of
TSC1 have been identified in 14.5% of bladder tumors
and loss of heterozygosity of TSC1 has been reported
approximately 54% of bladder cancers [21–26]. In this
study we showed that mutation and loss of TSC1 in
bladder cancer cells reduced the accumulation of Hsp90
inhibitors in these cells and decreased cell sensitivity to
Hsp90 inhibitors. We were able to rescue this effect by

Figure 3: Tsc1 facilitates acetylation of Hsp90-K407/K419. (A) Structure of an Hsp90 dimer (PDB:2CG9). K407 and K419 are

highlighted on one protomer in red. (B) FLAG-tagged Hsp90α-WT or non-acetylatable mutants K407A, K419A, or K407/K419A were
transfected into HSP90α KO HAP1 cells. Acetylation status was determined by immunoprecipitation and immunoblot. LE=long exposure,
SE=short exposure. (C) Tsc1 interaction with Hsp90 and acetylation mutants was assessed by FLAG immunoprecipitation of Hsp90 from
lysates in (B). (D) Hsp90 acetylation was determined by immunoprecipitation and immunoblot of Hsp90α-WT-FLAG and Hsp90α-K407/
K419A-FLAG from TSC1 WT and TSC1 KO HAP1 cells. (E) Lysates from Figure 3B were challenged with biotinylated-ganetespib.
Binding of Hsp90α-FLAG from these lysates to biotinylated-ganetespib was examined by immunoblot.
www.oncotarget.com
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Figure 4: HDAC inhibition rescues Hsp90 acetylation in TSC1-knock out cells. (A) Endogenous Hsp90 was immunoprecipitated

from HEK293 cells treated with or without 1 µM pan-HDAC inhibitor ACY-241 for 16 hr and its acetylation status was determined
by immunoblot. (B) Hsp90α-WT-FLAG and non-acetylatable mutant K407/K419A were transiently expressed in HEK293 cells in the
presence or absence of 1 µM ACY-241 for 16 hr. Acetylation status was evaluated by immunoprecipitation followed by immunoblot.
LE=long exposure, SE=short exposure. (C) TSC1 WT HAP1 cells and TSC1 KO HAP1 cells were treated with or without 1µM ACY-241
for 16 hr. Endogenous Hsp90 was isolated and its acetylation status was examined by immunoblot.

Figure 5: HDAC inhibition synergizes with Hsp90 inhibition to induce apoptosis in bladder cancer. (A) Sensitivity of T24, UM-

UC-3 and RT4 cells to increasing concentrations of ACY-241 was determined by WST proliferation assay. A Student’s t-test was performed to
assess statistical significance (***p < 0.001). (B) RT4 cells were treated with or without 0.5µM ACY-241 for 16 hr followed by 0.5µM ganetespib
for an additional 48 hr. Cell viability was then determined by WST proliferation assay. A Student’s t-test was performed to assess statistical
significance (***p < 0.001). (C) Immunoblot of apoptotic marker cleaved caspase-3 in RT4 cells from (B). (D) Hsp90 binding to biotinylatedganetespib was examined in RT4 cells treated with or without 1 µM ACY-241 for 16 hr. (E) Impact of the co-chaperone Tsc1 on Hsp90 binding
to its inhibitors. Tsc1 facilitates acetylation of Hsp90-K407/K419. In the absence of Tsc1, Hsp90 is hypoacetylated at these residues and binds
less avidly to its inhibitors. HDAC inhibitor treatment restores Hsp90 acetylation and bladder cancer cell sensitivity to Hsp90 inhibitors.
www.oncotarget.com
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bladder cancer cells with TSC1 mutation, 2) TSC1 KO
HAP1 cells, 3) conditional knockout of TSC1 in mouse
brain and 4) TSC1 KO MEFs. Interestingly the effect of
the Tsc1 mutation on Hsp90 acetylation appears to be Tsc1
specific and independent of the mTOR pathway, Hsp90
acetylation was unaffected both in TSC2 KO MEFs and in
HEK293 cells treated with the mTOR inhibitor rapamycin.
Hypoacetylation of Hsp90 enhances its ATPase
activity and reduces binding to its inhibitors. Determination
of precisely how Tsc1 loss leads to hypoacetylation of
Hsp90 and which HAT or HDAC enzymes are involved
will require further investigation. However, increasing
Hsp90 acetylation through HDAC inhibition with ACY241 resulted in enhanced Hsp90 inhibitor binding as well
as sensitization to Hsp90 inhibitors in the TSC1 mutated
RT4 bladder cancer cell line.
HDAC6 mediated deacetylation of Hsp90 and
regulation of its chaperone function has been reported
previously [31, 32]. In fact our data are also in agreement
with those published previously, confirming acetylation
of Hsp90 leads to its inhibition. Therefore based on
our findings presented here we would like to propose
the following model, where in the presence of Tsc1 cochaperone Hsp90 is acetylated and has a high affinity
towards its N-domain inhibitors such as ganetespib
(Figure 5E). Mutation and inactivation of TSC1, such as
those frequently observed in bladder cancer cells leads
to hypoacetylation of Hsp90, enhanced ATPase activity,
and reduced binding to inhibitors (Figure 5E). This also
reduces the sensitivity of bladder cancer cells to the
Hsp90 inhibitors. This suggests that TSC1 status may
predict sensitivity to Hsp90 inhibitors in bladder cancer.
Additionally, in those patients with TSC1 mutated bladder
cancer, inhibition of HDACs can potentially restore
Hsp90 acetylation and sensitivity to Hsp90 inhibitors.

KO, and wild-type HAP1 cells were acquired from
Horizon Discovery. HEK293, UM-UC-3, WT MEF,
TSC1 KO and TSC2 KO MEFs cells were grown in
Dulbecco’s Modified Eagle Medium (DMEM, Sigma–
Aldrich), T24 and RT4 cells were grown in McCoy’s 5A
Medium (Sigma–Aldrich) and HAP1 cells were grown
in Isocove’s Modified Dulbecco’s Medium (IMDM,
Gibco) supplemented with 10% fetal bovine serum (FBS,
Sigma–Aldrich). Cells were grown in a CellQ incubator
(Panasonic Healthcare) at 37° C in an atmosphere
containing 5% CO2.

Plasmids
Tsc1-FLAG was cloned into pcDNA3 using Tsc1FLAG-F–tatgcgggtaccatggattacaaggatgacgacgataaggga
gcccaacaagcaaatgtcggggagcttc; and Tsc1-FLAG-R–ta
tgcggggcccttagctgtgttcatgatgagtc. Tsc1-FLAG-L557Cfs,
HSP90α-FLAG-K407A, HSP90α-FLAG-K419A, and
HSP90α-FLAG-K407/K419A were generated by sitedirected mutagenesis using the following primers:
Tsc1-FLAG-L557Cfs-F–actcccatagactgccctgcggc;
Tsc1-FLAG-L557Cfs-R–gccgcagggcagtctatgggagt;
Hsp90α-FLAG-K407A-F–atgttgcaacaaagcgctattttgaaagttatc;
Hsp90α-FLAG-K407A-R–gataactttcaaaatagcgctttgttgcaac
at; Hsp90α-FLAG-K419A-F–aatttggtcaaagcttgcttagaactc;
Hsp90α-FLAG-K419A-R–gagttctaagcaagctttgaccaaatt.
Mutations were confirmed by DNA sequencing.

Transient transfection and siRNA knock-down
HEK293 cells were transiently transfected with
each construct using TransIT®-2020 (Mirus) transfection
reagent according to company protocol and incubated
at 37° C for 16 hours prior to protein extraction. Short
interfering RNA (siRNA) scramble control and TSC1
(Tsc1) targeting duplexes were purchased from GE
Dharmacon and suspended in provided buffer. For Tsc1
knock-down, either 30 nM of control siRNA or 10 nM
of each Tsc1 siRNA duplex (A, B and C) were mixed
prior to transfection. Cells were incubated at 37° C then
harvested for protein extraction (see below) or placed into
downstream applications as described below.

MATERIALS AND METHODS
Mice
All mouse experiments were performed under the
ethical guidelines of the Washington University School
of Medicine, and animal protocols were reviewed and
approved by the Washington University School of
Medicine Institutional Animal Care and Use Committee
(IACUC #A-3381-01; Protocol #20160091). All mice
used in this study were obtained from an existing breeding
colony of Tsc1GFAPCKO mice (Uhlmann et al, 2002; Zeng
et al, 2008) in the animal facility of the Washington
University School of Medicine.

Protein extraction, immunoprecipitation, and
immunoblotting
Protein extraction from mammalian cells was
carried out using methods previously described [30]. For
immunoprecipitation, protein lysates were incubated with
anti-FLAG M2 Affinity Gel agarose (Sigma) for 2 hr at
4° C. Alternatively, for endogenous immunoprecipitation,
protein lysate was incubated with Hsp90 antibody for
2 hr followed by incubation with protein G agarose
(Qiagen) for 2 hr at 4° C. Immunopellets were washed
4 times with fresh lysis buffer (20mM Tris (pH7.4), 100

Mammalian cell culture
Human embryonic kidney (HEK293), T24, UMUC-3, and RT4 cells were acquired from the American
Type Culture Collection (ATCC). TSC1 KO, HSP90α
www.oncotarget.com
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Hsp90 ATPase assay

mM NaCl, 1 mM MgCl2, 0.1% NP40, protease inhibitor
cocktail (Roche), and PhosSTOP (Roche)) and eluted
with 5× Laemmli buffer. Precipitated proteins were
separated by SDS-PAGE and transferred to nitrocellulose
membranes. Co-immunoprecipitated proteins were
detected by immunoblotting with indicated dilutions
of antibodies. Primary antibodies recognizing FLAG
1:8000 (ThermoFisher Scientific; PA1-984B), Hsp90835-16F1 1:8000 (ENZO Life Sciences; ADI-SPA-835),
GAPDH 1:8,000 (ENZO Life Sciences; ADI-CSA-335),
Tsc1 1:1000 (Cell Signaling Technology (CST); 4906),
Tsc2 1:1000 (CST; 3990), K-Ac 1:1000 (CST; 9441),
phos-Ser 1:1000 (Sigma; P5747), phos-Thr 1:1000
(Sigma; P6623), phos-Tyr 1:1000 (Millipore; 05-321),
Phospho-p70 S6 Kinase (Thr389) (108D2) 1:2000 (CST;
9234), p70S6K 1:6000 (SantaCruz Biotechnology;
sc-8418), and cleaved-caspase-3 1:1000 (CST; 9661)
were used for immunoblotting. Endogenous Hsp90 was
immunoprecipitated with Hsp90-835-16F1 (ENZO
Life Sciences; ADI-SPA-835) at 1:1000 dilution. HRPconjugated secondary antibodies raised against mouse,
rabbit, and rat (Cell Signaling Technology) were used at
1:4000 dilution.

ATPase activity of Hsp90 was measured as
previously described (Kamal et al. 2003) with the following
additional details. Following protein extraction and
immunoprecipitation as described above in the Materials
and Methods, protein-bound Protein-G agarose (Qiagen)
was washed five times in 0.5M NaCl and 1% NP-40
buffer. Proteins were eluted from the beads twice with
50µl 0.1M glycine pH 3.0 and immediately neutralized
using an equal volume of Tris pH 8.0. Protein was then
concentrated with Amicon® Ultra-2 mL, 10K centrifugal
filters (Millipore). Using the Micro BCATM Protein
Assay Kit (Thermo Scientific), protein was quantified to
standardize the amount of protein used in the assay. Assay
was performed as described in the PiPerTM Phosphate Assay
Kit instructions for use (Life Technologies). Standard
curve with linear fit line was created from 0-100µM final
concentration reactions. Hsp90 was incubated at 37°C
for 1 hr with 100mM ATP as substrate, with or without
10µM ganetespib (Synta Pharmaceuticals). ATP turnover
was calculated as mmol Pi per mol Hsp90 per minute, and
relative ATPase activity was calculated from those values,
with the value of Hsp90α alone representing 100% activity.

Fluorescence microscopy
T24 and UM-UC-3 cells were transiently
transfected with siRNA targeting Tsc1 and RT4 cells were
transfected with Tsc1-FLAG for 48 hr as described above,
then trypsinized and plated overnight on glass coverslips
(#1). After 16 hr, BODIPY-ganetespib was added to
cells at the indicated concentrations for an additional
4 hr. Cells were fixed in 4% paraformaldehyde for 20
minutes at room temperature and washed 3× with fresh
PBS. Coverslips were then mounted onto glass slides
using ProLong® Gold antifade mounting media with
DAPI (4′,6-diamidino-2-phenylindole) (ThermoFisher
Scientific). Images were obtained using a Zeiss LSM780
confocal microscope.

Cell proliferation colorimetric (WST) assay
T24, UM-UC-3 were seeded at 5,000 cell/well after
siRNA TSC1 knock-down and RT4 cells were seeded at
10,000 cells/well alone or after Tsc1-FLAG expression
as described above in 96-well plates. Cells were treated
with indicated concentrations of ACY-241 (Celgene
Corporation) and/or ganetespib as indicated. After 72 hr,
cell proliferation colorimetric (WST) assay was performed
according to the manufacturer’s protocol (BioVision, Cat#
K302-500). In brief, 10 μl WST was added to each well
and the plate was returned to the 37° C incubator. After 60
minutes, absorbance at 450nm was measured on a Tecan
Infinite M200 Pro and proliferation rate was calculated.
For transfected/siRNA knockdown cells, transfections
were incubated for 48 hours prior to trypsinization and
plating in the 96-well plate.
www.oncotarget.com

Quantification and statistical analysis
The relationship of drug co-treatment was
measured through an isobologram. The ED50 of each
drug was plotted in Cartesian co-ordinates on an X,
Y graph and a best fit line drawn. The co-ordinates of
the ED50 for the co-treatment of the drugs was further
plotted. The offset of the combined drugs from the best
fit line is given as the combination index with equation:
[ A]
[ B]
=
CI
+
ED50[ A] ED50[ B ] . The data presented are the
representative or examples of three biological replicates
unless it is specified. Data were analyzed with unpaired
Student’s t-test. Asterisks in figures indicate significant
differences (*p < 0.05, **p < 0.01, ***p < 0.001, and ***p <
0.0001). Error bars represent the standard deviation (S. D.)
for three independent experiments, unless it is indicated.
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